Nanobiotix (NASDAQ: NBTX) rejects media speculation about any takeover plans

Rhea-AI Filing Summary

Nanobiotix S.A. filed a Form 6-K to share a press release responding to media speculation about a potential public take-over of the company. Nanobiotix states that, to the best of its knowledge, there is no intention by any party to acquire control of the company and that no process or assessment toward such a transaction is underway.

The company also notes that it has identified factual inaccuracies in the media report, which it says are not consistent with its most recent public disclosures. Beyond this clarification, the filing mainly reiterates Nanobiotix’s profile as a late-stage clinical biotechnology company developing nanotechnology-based therapies for cancer and other serious diseases.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On March 25, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated March 25, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: March 25, 2026		/s/ Bart Van Rhijn
		Bart Van Rhijn
		Chief Financial Officer

EXHIBIT 99.1

NANOBIOTIX Statement Regarding Recent Media Speculation

PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today issued the following statement in response to recent media speculation concerning intentions for a potential public take-over.

Nanobiotix states that, to the best of its knowledge, there is no such intention to acquire control of the Company, and no process or assessment is being conducted toward that end. Additionally, the Company has identified factual inaccuracies in this media report which are not consistent with the Company’s most recent public disclosures.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 2, 2025 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2024 universal registration document filed with the AMF on April 2, 2025 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2025 filed on September 30, 2025 which are available on the SEC’s website at www.sec.gov and on the AMF's website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Communications Department
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com 

Attachment

• 2026-03-25 -- NBTX -- Statement Regarding Recent Media Rumor -- FINAL (https://ml.globenewswire.com/Resource/Download/bfa68747-33b5-40ac-b552-7df68dd20b82)

FAQ

What does Nanobiotix (NBTX) say about recent takeover rumors?

Nanobiotix states it is not aware of any intention to acquire control of the company. It adds that no process or assessment for a public take-over is underway, directly addressing and rejecting recent media speculation.

Did Nanobiotix (NBTX) confirm any takeover discussions in its Form 6-K?

Nanobiotix did not confirm any takeover discussions. Instead, it explicitly states there is no intention to acquire control of the company and no related process or assessment in progress, contradicting the recent media speculation.

How does Nanobiotix (NBTX) describe the media report mentioned in the 6-K?

Nanobiotix says it found factual inaccuracies in the media report. According to the company, these inaccuracies are not consistent with its most recent public disclosures, reinforcing its statement that no takeover process is underway.

What type of company is Nanobiotix (NBTX) according to this filing?

Nanobiotix describes itself as a late-stage clinical biotechnology company. It focuses on physics-based nanotherapeutic approaches, with more than 30 umbrella patents covering platforms in oncology, bioavailability and biodistribution, and central nervous system disorders.

On which stock exchanges is Nanobiotix (NBTX) listed?

Nanobiotix is listed on Euronext Paris and the Nasdaq Global Select Market. The company notes its Paris listing has been in place since 2012, and its Nasdaq listing began in December 2020, providing access to both European and U.S. investors.

Where is Nanobiotix (NBTX) headquartered and when was it incorporated?

Nanobiotix is headquartered in Paris, France, and was incorporated in 2003. The company also maintains subsidiaries, including one in Cambridge, Massachusetts, reflecting its international operational footprint in Europe and the United States.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.3 KB